135 related articles for article (PubMed ID: 26942141)
1. Prospective randomized trial to compare the outcome and tolerability of delivering the same total dose of radiation in 61/2 weeks versus 51/2 weeks time in head and neck cancers.
Gupta M; Vats S; Bhattacharyya T; Seem RK; Gupta M; Mahajan R
South Asian J Cancer; 2015; 4(3):118-22. PubMed ID: 26942141
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomized trial to compare accelerated (six fractions a week) radiotherapy against concurrent chemoradiotherapy (using conventional fractionation) in locally advanced head and neck cancers.
Gupta M; Mahajan R; Kaushal V; Seem RK; Gupta M; Bhattacharyya T
J Cancer Res Ther; 2015; 11(4):723-9. PubMed ID: 26881508
[TBL] [Abstract][Full Text] [Related]
3. Comparison of conventional fractionation (five fractions per week) and altered fractionation (six fractions per week) in stage I and II squamous cell carcinoma of oropharynx: An institutional study.
Poddar J; Sharma AD; Kunikullaya SU; Neema JP
Indian J Cancer; 2017; 54(1):6-10. PubMed ID: 29199652
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
[TBL] [Abstract][Full Text] [Related]
5. Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial.
Corvò R; Benasso M; Sanguineti G; Lionetto R; Bacigalupo A; Margarino G; Pallestrini E; Merlano M; Vitale V; Rosso R
Cancer; 2001 Dec; 92(11):2856-67. PubMed ID: 11753959
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two different radiation fractionation schedules with concurrent chemotherapy in head and neck malignancy.
Alam MS; Perween R; Siddiqui SA
Indian J Cancer; 2016; 53(2):265-269. PubMed ID: 28071624
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of the Toxicities in Patients With Locally Advanced Head and Neck Cancers Treated With Concomitant Boost Radiotherapy Versus Conventional Chemoradiation.
Sharma R; Vats S; Seam R; Gupta M; Negi RR; Fotedar V; Singh K
Cureus; 2023 Apr; 15(4):e38362. PubMed ID: 37266055
[TBL] [Abstract][Full Text] [Related]
8. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial.
Ghosh-Laskar S; Kalyani N; Gupta T; Budrukkar A; Murthy V; Sengar M; Chaukar D; Pai P; Chaturvedi P; D'Cruz A; Agarwal J
Head Neck; 2016 Feb; 38(2):202-7. PubMed ID: 25224814
[TBL] [Abstract][Full Text] [Related]
9. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.
Overgaard J; Hansen HS; Specht L; Overgaard M; Grau C; Andersen E; Bentzen J; Bastholt L; Hansen O; Johansen J; Andersen L; Evensen JF
Lancet; 2003 Sep; 362(9388):933-40. PubMed ID: 14511925
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of the treatment outcome of moderately accelerated radiation fractionation (with concurrent chemotherapy in daily dosing) to conventional chemo-radiotherapy in locally advanced head and neck cancers: Supportive in a resource constrained environment.
Arora C; Sharma N; Kapoor A; Pandya TN
Indian J Cancer; 2023 May; ():. PubMed ID: 38090961
[TBL] [Abstract][Full Text] [Related]
11. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial.
Horiot JC; Bontemps P; van den Bogaert W; Le Fur R; van den Weijngaert D; Bolla M; Bernier J; Lusinchi A; Stuschke M; Lopez-Torrecilla J; Begg AC; Pierart M; Collette L
Radiother Oncol; 1997 Aug; 44(2):111-21. PubMed ID: 9288839
[TBL] [Abstract][Full Text] [Related]
12. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial.
Overgaard J; Mohanti BK; Begum N; Ali R; Agarwal JP; Kuddu M; Bhasker S; Tatsuzaki H; Grau C
Lancet Oncol; 2010 Jun; 11(6):553-60. PubMed ID: 20382075
[TBL] [Abstract][Full Text] [Related]
13. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.
Fu KK; Pajak TF; Trotti A; Jones CU; Spencer SA; Phillips TL; Garden AS; Ridge JA; Cooper JS; Ang KK
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):7-16. PubMed ID: 10924966
[TBL] [Abstract][Full Text] [Related]
14. Different fractionation schedules of radiotherapy in locally advanced head and neck malignancy: A prospective randomized study to compare the results of treatment and toxicities of different protocols.
Majumder D; Choudhury K; Das P; Kundu S; Mitra D
South Asian J Cancer; 2013 Jan; 2(1):31-5. PubMed ID: 24455542
[TBL] [Abstract][Full Text] [Related]
15. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.
Lee DJ; Cosmatos D; Marcial VA; Fu KK; Rotman M; Cooper JS; Ortiz HG; Beitler JJ; Abrams RA; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):567-76. PubMed ID: 7790241
[TBL] [Abstract][Full Text] [Related]
16. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial.
Bourhis J; Lapeyre M; Tortochaux J; Rives M; Aghili M; Bourdin S; Lesaunier F; Benassi T; Lemanski C; Geoffrois L; Lusinchi A; Verrelle P; Bardet E; Julieron M; Wibault P; Luboinski M; Benhamou E
J Clin Oncol; 2006 Jun; 24(18):2873-8. PubMed ID: 16782926
[TBL] [Abstract][Full Text] [Related]
17. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study.
Poulsen MG; Denham JW; Peters LJ; Lamb DS; Spry NA; Hindley A; Krawitz H; Hamilton C; Keller J; Tripcony L; Walker Q
Radiother Oncol; 2001 Aug; 60(2):113-22. PubMed ID: 11439206
[TBL] [Abstract][Full Text] [Related]
18. Concurrent chemoradiation in locally advanced head and neck cancers: a comparative study of weekly Paclitaxel versus Cisplatin-based regimen.
Essa HH; Azzam M
J Egypt Natl Canc Inst; 2010 Sep; 22(3):165-73. PubMed ID: 21863067
[TBL] [Abstract][Full Text] [Related]
19. Concomitant boost radiotherapy compared with conventional radiotherapy in squamous cell carcinoma of the head and neck--a phase III trial from a single institution in India.
Ghoshal S; Goda JS; Mallick I; Kehwar TS; Sharma SC
Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):212-20. PubMed ID: 18343310
[TBL] [Abstract][Full Text] [Related]
20. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
